FDA Says No Cardio Risk with Olmesartan in Diabetes Patients
After completing a safety review, the US Food and Drug Administration (FDA) found no evidence that the blood pressure medication olmesartan increases cardiovascular risks in people with diabetes.
FDA Approves Label Changes to Blood Pressure Medicine Olmesartan Medoxomil
The US Food and Drug Administration (FDA) is warning that the blood pressure drug olmesartan medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy.
Heart Drug Linked to Celiac Symptoms
A popular medication that can help with high blood pressure may also cause severe gastrointestinal problems such as nausea, vomiting, diarrhea, weight loss and electrolyte abnormalities. But why?
FDA Drug Safety Communication: Benicar
After reviewing the results of the ROADMAP and ORIENT trials, the FDA has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label. Benicar is not recommended as a treatment to delay or prevent protein in the urine ( microalbuminuria ) in diabetic patients. Patients should consult their healthcare professional if they have any questions or concerns about taking Benicar . Daiichi Sankyo , the makers of Benicar , have agreed to work with the FDA to perform additional ...